Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through NLRP3 Inflammasome-Mediated Pyroptosis Inhibition via Activating Nrf2

Figure 4

AST IV promotes Nrf2 activation in CIRI. (a) Western blot assay showing the Nrf2 levels in the nuclear and total protein fractions. (b, c) Quantitative analysis of Nrf2 levels in the nuclear, normalized to Lamin B1 and total protein fractions, normalized to β-actin. Values are , . vs. the sham group; ^#, ^## vs. the MCAO/R group. (d) Immunofluorescence imaging of Nrf2 nuclear colocalization. SH-SY5Y cells were randomly assigned to the following groups: the sham group (complete medium), the OGD/R group (complete medium), the OGD/R + AST IV group (20 μg/ml AST IV was administered 24 h before OGD, OGD was performed for 2 h, and 20 μg/ml AST IV was administered at 24 h just after OGD to achieve reperfusion), and the OGD/R +20 μg/ml AST IV+20 μM ML385 group (20 μg/ml AST IV+20 μM ML385) was administered 24 h before OGD, OGD was performed for 2 h, and 20 μg/ml AST IV+20 μM ML385 was administered at 24 h just after OGD to achieve reperfusion. (e) Intracellular ROS stained via DCFH-DA. (f) Quantitative analysis of Nrf2 nuclear immunofluorescence intensity. Values are , . vs. the sham group; ^## vs. the OGD/R group; ^&& vs. the AST IV group. (g) Representative quantification of cellular ROS contents. Values are , . vs. the sham group; ^## vs. the OGD/R group; ^&& vs. the AST IV group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)